サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1794638

真性多血症薬の世界市場

Polycythemia Vera Drugs

出版日
ページ情報
英文 272 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=149.79円
真性多血症薬の世界市場
出版日: 2025年08月20日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 272 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

真性多血症薬の世界市場は2030年までに14億米ドルに達する

2024年に11億米ドルと推定された真性多血症薬の世界市場は、2024～2030年の分析期間にCAGR 3.2%で成長し、2030年には14億米ドルに達すると予測されます。本レポートで分析したセグメントの1つであるダサチニブは、CAGR 2.9%を記録し、分析期間終了時には5億5,730万米ドルに達すると予想されます。イデラリシブセグメントの成長率は、分析期間中CAGR 2.5%と推定されます。

米国市場は3億890万米ドルと推定され、中国はCAGR 5.9％で成長すると予測される

米国の真性多血症薬市場は、2024年に3億890万米ドルと推定されます。世界第2位の経済大国である中国は、分析期間2024-2030年のCAGR 5.9%を牽引し、2030年までに2億6,850万米ドルの市場規模に達すると予測されています。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ1.3%と2.4%と予測されています。欧州では、ドイツがCAGR 1.8%で成長すると予測されています。

世界の真性多血症薬市場- 主要動向と促進要因のまとめ

クローン血流を標的とする：新たな治療法はいかにしてベラ多血症治療の展望を再構築しつつあるか

なぜ真性多血症の医薬品開発は戦略的に拡大しつつあるのか？

慢性骨髄増殖性新生物（MPN）である真性多血症（PV）は、骨髄における赤血球前駆体のクローン性増殖を特徴とし、過剰な赤血球産生をもたらします。患者の大部分はJAK2 V617F変異を有し、JAK-STATシグナル伝達経路の構成的活性化とサイトカイン過敏症をもたらします。薬理学的介入は、血栓リスクを軽減し、ヘマトクリット値をコントロールし、そう痒症、疲労、脾腫などの症状負担を軽減することを目的としています。対症療法だけでなく、疾患修飾療法が臨床的に重視されるようになったことで、治療法が拡大し、血液腫瘍学における真性多血症薬の役割が高まっています。瀉血と低用量アスピリンは依然として低リスク患者に対する第一選択の管理手段であるが、高リスク症例（60歳以上または血栓性イベントの既往により定義される）には細胞還元療法が必要です。ヒドロキシ尿素は伝統的に最も標準的な細胞還元療法薬であったが、耐性、不耐性、および長期的な白血病発症リスクに対する懸念の高まりにより、JAK阻害剤、インターフェロン、および現在研究中の新規低分子化合物などの新しい標的治療薬に対する需要が加速しています。

PVの治療アルゴリズムを支配している薬剤クラスと治療プロトコールは？

ヒドロキシ尿素は、血液学的コントロールと経口投与の利便性から、第一選択薬として最も広く処方されています。しかし、患者の約20～25％がヒドロキシ尿素に耐性または不耐性を示すため、第二選択薬への移行が促されています。選択的JAK1/JAK2阻害薬であるルキソリチニブは、ヒドロキシ尿素不応性PVに対する主要な治療薬として登場しました。RESPONSEおよびRESPONSE-2臨床試験に基づいて承認されたルキソリチニブは、ヘマトクリット値を効果的に低下させ、脾腫を縮小させ、QOL指標を改善します。ペグインターフェロンα-2aやロペグインターフェロンα-2bを含むインターフェロンベースの治療は、クローン性造血を標的とすることで疾患修飾効果をもたらす可能性があります。特にロペグインターフェロンは、血液学的および分子学的寛解の達成において有望な長期成績を示しており、若年患者や化学療法不要のレジメンを求める患者にとって実行可能な選択肢となっています。その隔週投与スケジュールは、旧型のインターフェロンと比較してコンプライアンスを向上させる。アスピリンは血栓予防のためにすべてのリスク群で不可欠であり、一方、低分子ヘパリン（LMWH）は急性血栓事象に使用されます。ヘプシジン模倣薬（例えば、PTG-300）やヒストン脱アセチル化酵素阻害薬などの新しい治験薬は、それぞれ鉄代謝を調節し、骨髄増殖促進を抑制する能力について評価されています。

バイオマーカーを用いた戦略や個別化治療はPV管理をどのように変えていくのか？

個別化医療は、ゲノムマーカー、血液マーカー、分子マーカーを治療方針の決定に統合することで、PVの治療戦略を再構築しています。JAK2変異負荷、対立遺伝子頻度、TET2、ASXL1、DNMT3Aなどのエピジェネティック制御因子における同時変異は、リスクの層別化、骨髄線維症や急性骨髄性白血病（AML）への進行予測、治療効果の評価にますます用いられるようになっています。定量的PCR法に基づくJAK2 V617F追跡による微小残存病変（MRD）のモニタリングは、特にインターフェロンまたはJAK阻害剤治療中の患者を対象として、先進施設で採用されつつあります。MPN-SAF（骨髄増殖性新生物症状評価フォーム）のような症状スコアと血液学的パラメータを併用することで、患者が報告する転帰に合わせて治療を調整するのに役立っています。遠隔症状追跡、ヘマトクリットの遠隔モニタリング、意思決定支援アルゴリズムなどのデジタルヘルスツールは、動的な用量漸増と治療抵抗性の早期同定を支援しています。これらのツールは、学術機関や地域社会における包括的なPV管理プロトコールに統合されつつあります。

世界の重症多血症治療薬の成長を支える主な要因は何か？

真性多血症薬市場の成長を牽引しているのは、疾患に対する認識の高まり、標的治療の進歩、分子診断へのアクセスの拡大、MPN研究への投資の増加です。主な促進要因としては、PVが長期的な管理と病状の変化の可能性を必要とする慢性悪性腫瘍であるとの認識が高まっていることが挙げられます。この再分類により、特に若年で症状のある患者において、薬物療法の早期開始が促されています。ルキソリチニブとロペジンターフェロンが複数の地域で承認・償還されたことで、治療へのアクセスは拡大しつつあり、持続的な血液学的・症状コントロールを示す実臨床のエビデンスに支えられています。さらに、鉄代謝、エピジェネティクス異常、炎症シグナル伝達を標的とする新規メカニズムのパイプライン薬剤が、血液内科専門医や製薬利害関係者の関心を集めています。地域がん診療の現場における遺伝子検査インフラの拡大により、より多くの患者が正確に診断され、層別化されるようになっています。欧州、アジア、ラテンアメリカでは、PV療法が国のがん治療計画や血液学ガイドラインに組み込まれ、薬剤市場の浸透が進んでいます。さらに、併用レジメンや早期治療を検討する臨床試験が進行中であり、治療パラダイムの転換と市場成長の加速が期待されます。PVがリスク軽減モデルからプレシジョン・オンコロジーの枠組みへと移行するにつれて、差別化され、耐久性があり、忍容性のある治療薬への需要が強まり、専門医療とプライマリ・ケアの両方のオンコロジー・チャネルに新たな機会が創出されるであろう。

セグメント

薬剤タイプ（ダサチニブ、イデラリシブ、ジビノスタット、その他のタイプ）、エンドユーザー（病院・診療所、外来手術センター、その他のエンドユーザー）

調査対象企業の例

  • AbbVie Inc.
  • Allarity Therapeutics Inc.
  • Amgen Inc.
  • AstraZeneca Plc
  • Bayer AG
  • BeiGene Ltd.
  • Bristol Myers Squibb（Clovis Oncology）
  • Daiichi Sankyo Co., Ltd.
  • Gilead Sciences, Inc.
  • GlaxoSmithKline Plc
  • Incyte Corporation
  • Ionis Pharmaceuticals Inc.
  • Karyopharm Therapeutics Inc.
  • Merck & Co., Inc.
  • Novartis AG
  • PharmaEssentia Corporation
  • Pfizer Inc.
  • Protagonist Therapeutics Inc.
  • Silence Therapeutics Plc
  • Zai Lab Ltd.

AIインテグレーション

当社は、有効な専門家コンテンツとAIツールにより、市場情報と競合情報を変革しています。

Global Industry Analystsは、LLMや業界固有のSLMを照会する一般的な規範に従う代わりに、ビデオ記録、ブログ、検索エンジン調査、膨大な量の企業、製品/サービス、市場データなど、世界中の専門家からキュレートされたコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP37771

Global Polycythemia Vera Drugs Market to Reach US$1.4 Billion by 2030

The global market for Polycythemia Vera Drugs estimated at US$1.1 Billion in the year 2024, is expected to reach US$1.4 Billion by 2030, growing at a CAGR of 3.2% over the analysis period 2024-2030. Dasatinib, one of the segments analyzed in the report, is expected to record a 2.9% CAGR and reach US$557.3 Million by the end of the analysis period. Growth in the Idelalisib segment is estimated at 2.5% CAGR over the analysis period.

The U.S. Market is Estimated at US$308.9 Million While China is Forecast to Grow at 5.9% CAGR

The Polycythemia Vera Drugs market in the U.S. is estimated at US$308.9 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$268.5 Million by the year 2030 trailing a CAGR of 5.9% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.3% and 2.4% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.8% CAGR.

Global Polycythemia Vera Drugs Market - Key Trends & Drivers Summarized

Targeting the Clonal Bloodstream: How Emerging Therapies Are Reshaping the Polycythemia Vera Treatment Landscape

Why Is the Drug Development Landscape for Polycythemia Vera Witnessing Strategic Expansion?

Polycythemia vera (PV), a chronic myeloproliferative neoplasm (MPN), is characterized by clonal proliferation of erythroid precursors in the bone marrow, leading to excessive red blood cell production. The majority of patients harbor JAK2 V617F mutations, resulting in constitutive activation of the JAK-STAT signaling pathway and cytokine hypersensitivity. Pharmacological interventions aim to reduce thrombotic risks, control hematocrit levels, and alleviate symptom burden such as pruritus, fatigue, and splenomegaly. The increasing clinical emphasis on disease-modifying therapies-rather than symptomatic control alone-has expanded the therapeutic landscape and elevated the role of polycythemia vera drugs in hematologic oncology. While phlebotomy and low-dose aspirin remain first-line management tools for low-risk patients, high-risk cases-defined by age over 60 or history of thrombotic events-require cytoreductive therapy. Hydroxyurea has traditionally been the gold-standard cytoreductive agent, but growing concerns over resistance, intolerance, and long-term leukemogenic risk have accelerated the demand for newer targeted therapies such as JAK inhibitors, interferons, and novel small molecules under investigation.

Which Classes of Drugs and Treatment Protocols Are Dominating the PV Therapeutic Algorithm?

Hydroxyurea remains the most widely prescribed first-line cytoreductive therapy due to its hematologic control and oral dosing convenience. However, approximately 20-25% of patients exhibit resistance or intolerance to hydroxyurea, prompting a shift toward second-line options. Ruxolitinib, a selective JAK1/JAK2 inhibitor, has emerged as the leading therapy for hydroxyurea-refractory PV. Approved based on the RESPONSE and RESPONSE-2 clinical trials, ruxolitinib effectively reduces hematocrit levels, shrinks splenomegaly, and improves quality of life metrics. Interferon-based therapies, including pegylated interferon alpha-2a and ropeginterferon alpha-2b, offer potential disease-modifying effects by targeting clonal hematopoiesis. Ropeginterferon, in particular, has shown promising long-term results in achieving hematologic and molecular remissions, making it a viable option for younger patients or those seeking chemotherapy-free regimens. Its biweekly dosing schedule also enhances compliance compared to older interferon variants. Aspirin remains essential in all risk groups for thromboprophylaxis, while low-molecular-weight heparins (LMWH) may be used in acute thrombotic events. Emerging investigational agents, such as hepcidin mimetics (e.g., PTG-300) and histone deacetylase inhibitors, are being evaluated for their ability to regulate iron metabolism and suppress myeloproliferative drive, respectively.

How Are Biomarker-Guided Strategies and Personalized Therapies Transforming PV Management?

Personalized medicine is reshaping PV treatment strategies by integrating genomic, hematologic, and molecular markers into therapeutic decisions. JAK2 mutation burden, allele frequency, and co-mutations in epigenetic regulators such as TET2, ASXL1, and DNMT3A are increasingly used to stratify risk, predict progression to myelofibrosis or acute myeloid leukemia (AML), and assess treatment response. Monitoring minimal residual disease (MRD) through quantitative PCR-based JAK2 V617F tracking is gaining adoption in advanced centers, particularly for patients on interferon or JAK inhibitor therapy. The use of hematologic parameters in conjunction with symptom scores such as MPN-SAF (Myeloproliferative Neoplasm Symptom Assessment Form) is helping tailor therapy to patient-reported outcomes. Digital health tools, including remote symptom tracking, telemonitoring of hematocrit, and decision-support algorithms, are supporting dynamic dose titration and early identification of therapy resistance. These tools are being integrated into comprehensive PV management protocols in academic and community settings.

What Are the Principal Drivers Supporting the Growth of Polycythemia Vera Therapeutics Globally?

The growth in the polycythemia vera drugs market is driven by rising disease awareness, advances in targeted therapies, expanded access to molecular diagnostics, and increasing investments in MPN research. A major driver is the growing recognition of PV as a chronic malignancy requiring long-term management and potential disease modification. This reclassification is prompting earlier initiation of pharmacologic therapy, especially in younger, symptomatic patients. The approval and reimbursement of ruxolitinib and ropeginterferon in multiple geographies are expanding therapeutic access, supported by real-world evidence showing sustained hematologic and symptom control. Furthermore, pipeline agents with novel mechanisms-targeting iron metabolism, epigenetic dysregulation, and inflammatory signaling-are attracting interest from hematology specialists and pharmaceutical stakeholders alike. Expansion of genetic testing infrastructure in community oncology settings is enabling more patients to be accurately diagnosed and stratified. Integration of PV therapy into national cancer plans and hematology guidelines across Europe, Asia, and Latin America is increasing drug market penetration. Additionally, ongoing clinical trials investigating combination regimens and earlier-line therapy are expected to shift treatment paradigms and accelerate market growth. As PV transitions from a risk-mitigation model to a precision oncology framework, the demand for differentiated, durable, and tolerable therapies will intensify-creating new opportunities across both specialty and primary care oncology channels.

SCOPE OF STUDY:

The report analyzes the Polycythemia Vera Drugs market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Drug Type (Dasatinib, Idelalisib, Givinostat, Other Types); End-Use (Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 32 Featured) -

  • AbbVie Inc.
  • Allarity Therapeutics Inc.
  • Amgen Inc.
  • AstraZeneca Plc
  • Bayer AG
  • BeiGene Ltd.
  • Bristol Myers Squibb (Clovis Oncology)
  • Daiichi Sankyo Co., Ltd.
  • Gilead Sciences, Inc.
  • GlaxoSmithKline Plc
  • Incyte Corporation
  • Ionis Pharmaceuticals Inc.
  • Karyopharm Therapeutics Inc.
  • Merck & Co., Inc.
  • Novartis AG
  • PharmaEssentia Corporation
  • Pfizer Inc.
  • Protagonist Therapeutics Inc.
  • Silence Therapeutics Plc
  • Zai Lab Ltd.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Polycythemia Vera Drugs - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Incidence of Myeloproliferative Disorders Expands Addressable Market for Polycythemia Vera Drugs
    • Increased JAK2 Mutation Testing Drives Early Diagnosis and Treatment Initiation
    • Development of Next-Generation JAK Inhibitors Strengthens Business Case for Targeted Therapy
    • Growing Focus on Cytoreductive Therapies Spurs Demand for Combination Treatment Regimens
    • Regulatory Approvals of Novel Agents Accelerate Product Launches and Market Penetration
    • Expansion of Hematology and Oncology Centers Enhances Treatment Accessibility
    • Real-World Evidence Studies and Longitudinal Registries Promote Treatment Optimization
    • Government Incentives for Orphan Drugs Drive Innovation in Rare Disease Therapeutics
    • Rising Patient Awareness of Blood Cancer Symptoms Spurs Early Clinical Consultation
    • Increased Reimbursement Support for Specialty Oncology Drugs Drives Adoption Rates
    • Advancements in Molecular Profiling Throw the Spotlight on Personalized Therapeutic Pathways
    • Ongoing Clinical Trials in Combination Therapies Strengthen Pipeline Diversity
    • Collaborations Between Biotech Firms and Academic Institutions Fuel Drug Development
    • Pharmacovigilance and Post-Marketing Surveillance Mandates Enhance Drug Safety Framework
    • Rising Use of Phlebotomy and Hydroxyurea Creates Baseline Demand for Maintenance Therapies
    • Patient-Centric Drug Delivery Models Generate Interest in Oral and Subcutaneous Formulations
    • Adoption of Telemedicine and e-Prescriptions Sustains Drug Access in Remote Regions
    • Expansion of Patient Support Programs by Pharma Companies Promotes Adherence
    • Increasing Investment in Rare Hematological Disorders Unlocks Long-Term Market Potential
    • Regulatory Harmonization in Emerging Markets Facilitates Global Access to New Therapies
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Polycythemia Vera Drugs Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Polycythemia Vera Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Polycythemia Vera Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 4: World 16-Year Perspective for Polycythemia Vera Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Dasatinib by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Dasatinib by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 7: World 16-Year Perspective for Dasatinib by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Idelalisib by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Idelalisib by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 10: World 16-Year Perspective for Idelalisib by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Givinostat by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Givinostat by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 13: World 16-Year Perspective for Givinostat by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Other Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Other Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 16: World 16-Year Perspective for Other Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Hospitals & Clinics End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Hospitals & Clinics End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 19: World 16-Year Perspective for Hospitals & Clinics End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Ambulatory Surgery Centers End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Ambulatory Surgery Centers End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 22: World 16-Year Perspective for Ambulatory Surgery Centers End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 25: World 16-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Polycythemia Vera Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 26: USA Recent Past, Current & Future Analysis for Polycythemia Vera Drugs by Drug Type - Dasatinib, Idelalisib, Givinostat and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 27: USA Historic Review for Polycythemia Vera Drugs by Drug Type - Dasatinib, Idelalisib, Givinostat and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 28: USA 16-Year Perspective for Polycythemia Vera Drugs by Drug Type - Percentage Breakdown of Value Sales for Dasatinib, Idelalisib, Givinostat and Other Types for the Years 2014, 2025 & 2030
    • TABLE 29: USA Recent Past, Current & Future Analysis for Polycythemia Vera Drugs by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 30: USA Historic Review for Polycythemia Vera Drugs by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 31: USA 16-Year Perspective for Polycythemia Vera Drugs by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • CANADA
    • TABLE 32: Canada Recent Past, Current & Future Analysis for Polycythemia Vera Drugs by Drug Type - Dasatinib, Idelalisib, Givinostat and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Canada Historic Review for Polycythemia Vera Drugs by Drug Type - Dasatinib, Idelalisib, Givinostat and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 34: Canada 16-Year Perspective for Polycythemia Vera Drugs by Drug Type - Percentage Breakdown of Value Sales for Dasatinib, Idelalisib, Givinostat and Other Types for the Years 2014, 2025 & 2030
    • TABLE 35: Canada Recent Past, Current & Future Analysis for Polycythemia Vera Drugs by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 36: Canada Historic Review for Polycythemia Vera Drugs by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 37: Canada 16-Year Perspective for Polycythemia Vera Drugs by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • JAPAN
    • Polycythemia Vera Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 38: Japan Recent Past, Current & Future Analysis for Polycythemia Vera Drugs by Drug Type - Dasatinib, Idelalisib, Givinostat and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Japan Historic Review for Polycythemia Vera Drugs by Drug Type - Dasatinib, Idelalisib, Givinostat and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 40: Japan 16-Year Perspective for Polycythemia Vera Drugs by Drug Type - Percentage Breakdown of Value Sales for Dasatinib, Idelalisib, Givinostat and Other Types for the Years 2014, 2025 & 2030
    • TABLE 41: Japan Recent Past, Current & Future Analysis for Polycythemia Vera Drugs by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 42: Japan Historic Review for Polycythemia Vera Drugs by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 43: Japan 16-Year Perspective for Polycythemia Vera Drugs by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • CHINA
    • Polycythemia Vera Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 44: China Recent Past, Current & Future Analysis for Polycythemia Vera Drugs by Drug Type - Dasatinib, Idelalisib, Givinostat and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 45: China Historic Review for Polycythemia Vera Drugs by Drug Type - Dasatinib, Idelalisib, Givinostat and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 46: China 16-Year Perspective for Polycythemia Vera Drugs by Drug Type - Percentage Breakdown of Value Sales for Dasatinib, Idelalisib, Givinostat and Other Types for the Years 2014, 2025 & 2030
    • TABLE 47: China Recent Past, Current & Future Analysis for Polycythemia Vera Drugs by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 48: China Historic Review for Polycythemia Vera Drugs by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 49: China 16-Year Perspective for Polycythemia Vera Drugs by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • EUROPE
    • Polycythemia Vera Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 50: Europe Recent Past, Current & Future Analysis for Polycythemia Vera Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 51: Europe Historic Review for Polycythemia Vera Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 52: Europe 16-Year Perspective for Polycythemia Vera Drugs by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
    • TABLE 53: Europe Recent Past, Current & Future Analysis for Polycythemia Vera Drugs by Drug Type - Dasatinib, Idelalisib, Givinostat and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Europe Historic Review for Polycythemia Vera Drugs by Drug Type - Dasatinib, Idelalisib, Givinostat and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 55: Europe 16-Year Perspective for Polycythemia Vera Drugs by Drug Type - Percentage Breakdown of Value Sales for Dasatinib, Idelalisib, Givinostat and Other Types for the Years 2014, 2025 & 2030
    • TABLE 56: Europe Recent Past, Current & Future Analysis for Polycythemia Vera Drugs by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Europe Historic Review for Polycythemia Vera Drugs by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 58: Europe 16-Year Perspective for Polycythemia Vera Drugs by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • FRANCE
    • Polycythemia Vera Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 59: France Recent Past, Current & Future Analysis for Polycythemia Vera Drugs by Drug Type - Dasatinib, Idelalisib, Givinostat and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 60: France Historic Review for Polycythemia Vera Drugs by Drug Type - Dasatinib, Idelalisib, Givinostat and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 61: France 16-Year Perspective for Polycythemia Vera Drugs by Drug Type - Percentage Breakdown of Value Sales for Dasatinib, Idelalisib, Givinostat and Other Types for the Years 2014, 2025 & 2030
    • TABLE 62: France Recent Past, Current & Future Analysis for Polycythemia Vera Drugs by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 63: France Historic Review for Polycythemia Vera Drugs by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 64: France 16-Year Perspective for Polycythemia Vera Drugs by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • GERMANY
    • Polycythemia Vera Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 65: Germany Recent Past, Current & Future Analysis for Polycythemia Vera Drugs by Drug Type - Dasatinib, Idelalisib, Givinostat and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Germany Historic Review for Polycythemia Vera Drugs by Drug Type - Dasatinib, Idelalisib, Givinostat and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 67: Germany 16-Year Perspective for Polycythemia Vera Drugs by Drug Type - Percentage Breakdown of Value Sales for Dasatinib, Idelalisib, Givinostat and Other Types for the Years 2014, 2025 & 2030
    • TABLE 68: Germany Recent Past, Current & Future Analysis for Polycythemia Vera Drugs by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Germany Historic Review for Polycythemia Vera Drugs by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 70: Germany 16-Year Perspective for Polycythemia Vera Drugs by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • ITALY
    • TABLE 71: Italy Recent Past, Current & Future Analysis for Polycythemia Vera Drugs by Drug Type - Dasatinib, Idelalisib, Givinostat and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Italy Historic Review for Polycythemia Vera Drugs by Drug Type - Dasatinib, Idelalisib, Givinostat and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 73: Italy 16-Year Perspective for Polycythemia Vera Drugs by Drug Type - Percentage Breakdown of Value Sales for Dasatinib, Idelalisib, Givinostat and Other Types for the Years 2014, 2025 & 2030
    • TABLE 74: Italy Recent Past, Current & Future Analysis for Polycythemia Vera Drugs by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Italy Historic Review for Polycythemia Vera Drugs by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 76: Italy 16-Year Perspective for Polycythemia Vera Drugs by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • UNITED KINGDOM
    • Polycythemia Vera Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 77: UK Recent Past, Current & Future Analysis for Polycythemia Vera Drugs by Drug Type - Dasatinib, Idelalisib, Givinostat and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 78: UK Historic Review for Polycythemia Vera Drugs by Drug Type - Dasatinib, Idelalisib, Givinostat and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 79: UK 16-Year Perspective for Polycythemia Vera Drugs by Drug Type - Percentage Breakdown of Value Sales for Dasatinib, Idelalisib, Givinostat and Other Types for the Years 2014, 2025 & 2030
    • TABLE 80: UK Recent Past, Current & Future Analysis for Polycythemia Vera Drugs by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 81: UK Historic Review for Polycythemia Vera Drugs by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 82: UK 16-Year Perspective for Polycythemia Vera Drugs by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • SPAIN
    • TABLE 83: Spain Recent Past, Current & Future Analysis for Polycythemia Vera Drugs by Drug Type - Dasatinib, Idelalisib, Givinostat and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Spain Historic Review for Polycythemia Vera Drugs by Drug Type - Dasatinib, Idelalisib, Givinostat and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 85: Spain 16-Year Perspective for Polycythemia Vera Drugs by Drug Type - Percentage Breakdown of Value Sales for Dasatinib, Idelalisib, Givinostat and Other Types for the Years 2014, 2025 & 2030
    • TABLE 86: Spain Recent Past, Current & Future Analysis for Polycythemia Vera Drugs by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Spain Historic Review for Polycythemia Vera Drugs by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 88: Spain 16-Year Perspective for Polycythemia Vera Drugs by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • RUSSIA
    • TABLE 89: Russia Recent Past, Current & Future Analysis for Polycythemia Vera Drugs by Drug Type - Dasatinib, Idelalisib, Givinostat and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Russia Historic Review for Polycythemia Vera Drugs by Drug Type - Dasatinib, Idelalisib, Givinostat and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 91: Russia 16-Year Perspective for Polycythemia Vera Drugs by Drug Type - Percentage Breakdown of Value Sales for Dasatinib, Idelalisib, Givinostat and Other Types for the Years 2014, 2025 & 2030
    • TABLE 92: Russia Recent Past, Current & Future Analysis for Polycythemia Vera Drugs by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Russia Historic Review for Polycythemia Vera Drugs by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 94: Russia 16-Year Perspective for Polycythemia Vera Drugs by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • REST OF EUROPE
    • TABLE 95: Rest of Europe Recent Past, Current & Future Analysis for Polycythemia Vera Drugs by Drug Type - Dasatinib, Idelalisib, Givinostat and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Rest of Europe Historic Review for Polycythemia Vera Drugs by Drug Type - Dasatinib, Idelalisib, Givinostat and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 97: Rest of Europe 16-Year Perspective for Polycythemia Vera Drugs by Drug Type - Percentage Breakdown of Value Sales for Dasatinib, Idelalisib, Givinostat and Other Types for the Years 2014, 2025 & 2030
    • TABLE 98: Rest of Europe Recent Past, Current & Future Analysis for Polycythemia Vera Drugs by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Rest of Europe Historic Review for Polycythemia Vera Drugs by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 100: Rest of Europe 16-Year Perspective for Polycythemia Vera Drugs by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • ASIA-PACIFIC
    • Polycythemia Vera Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 101: Asia-Pacific Recent Past, Current & Future Analysis for Polycythemia Vera Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 102: Asia-Pacific Historic Review for Polycythemia Vera Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 103: Asia-Pacific 16-Year Perspective for Polycythemia Vera Drugs by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
    • TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for Polycythemia Vera Drugs by Drug Type - Dasatinib, Idelalisib, Givinostat and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Asia-Pacific Historic Review for Polycythemia Vera Drugs by Drug Type - Dasatinib, Idelalisib, Givinostat and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 106: Asia-Pacific 16-Year Perspective for Polycythemia Vera Drugs by Drug Type - Percentage Breakdown of Value Sales for Dasatinib, Idelalisib, Givinostat and Other Types for the Years 2014, 2025 & 2030
    • TABLE 107: Asia-Pacific Recent Past, Current & Future Analysis for Polycythemia Vera Drugs by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Asia-Pacific Historic Review for Polycythemia Vera Drugs by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 109: Asia-Pacific 16-Year Perspective for Polycythemia Vera Drugs by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • AUSTRALIA
    • Polycythemia Vera Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 110: Australia Recent Past, Current & Future Analysis for Polycythemia Vera Drugs by Drug Type - Dasatinib, Idelalisib, Givinostat and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Australia Historic Review for Polycythemia Vera Drugs by Drug Type - Dasatinib, Idelalisib, Givinostat and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 112: Australia 16-Year Perspective for Polycythemia Vera Drugs by Drug Type - Percentage Breakdown of Value Sales for Dasatinib, Idelalisib, Givinostat and Other Types for the Years 2014, 2025 & 2030
    • TABLE 113: Australia Recent Past, Current & Future Analysis for Polycythemia Vera Drugs by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Australia Historic Review for Polycythemia Vera Drugs by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 115: Australia 16-Year Perspective for Polycythemia Vera Drugs by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • INDIA
    • Polycythemia Vera Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 116: India Recent Past, Current & Future Analysis for Polycythemia Vera Drugs by Drug Type - Dasatinib, Idelalisib, Givinostat and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 117: India Historic Review for Polycythemia Vera Drugs by Drug Type - Dasatinib, Idelalisib, Givinostat and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 118: India 16-Year Perspective for Polycythemia Vera Drugs by Drug Type - Percentage Breakdown of Value Sales for Dasatinib, Idelalisib, Givinostat and Other Types for the Years 2014, 2025 & 2030
    • TABLE 119: India Recent Past, Current & Future Analysis for Polycythemia Vera Drugs by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 120: India Historic Review for Polycythemia Vera Drugs by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 121: India 16-Year Perspective for Polycythemia Vera Drugs by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • SOUTH KOREA
    • TABLE 122: South Korea Recent Past, Current & Future Analysis for Polycythemia Vera Drugs by Drug Type - Dasatinib, Idelalisib, Givinostat and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 123: South Korea Historic Review for Polycythemia Vera Drugs by Drug Type - Dasatinib, Idelalisib, Givinostat and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 124: South Korea 16-Year Perspective for Polycythemia Vera Drugs by Drug Type - Percentage Breakdown of Value Sales for Dasatinib, Idelalisib, Givinostat and Other Types for the Years 2014, 2025 & 2030
    • TABLE 125: South Korea Recent Past, Current & Future Analysis for Polycythemia Vera Drugs by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 126: South Korea Historic Review for Polycythemia Vera Drugs by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 127: South Korea 16-Year Perspective for Polycythemia Vera Drugs by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 128: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Polycythemia Vera Drugs by Drug Type - Dasatinib, Idelalisib, Givinostat and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Rest of Asia-Pacific Historic Review for Polycythemia Vera Drugs by Drug Type - Dasatinib, Idelalisib, Givinostat and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 130: Rest of Asia-Pacific 16-Year Perspective for Polycythemia Vera Drugs by Drug Type - Percentage Breakdown of Value Sales for Dasatinib, Idelalisib, Givinostat and Other Types for the Years 2014, 2025 & 2030
    • TABLE 131: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Polycythemia Vera Drugs by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Rest of Asia-Pacific Historic Review for Polycythemia Vera Drugs by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 133: Rest of Asia-Pacific 16-Year Perspective for Polycythemia Vera Drugs by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • LATIN AMERICA
    • Polycythemia Vera Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 134: Latin America Recent Past, Current & Future Analysis for Polycythemia Vera Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 135: Latin America Historic Review for Polycythemia Vera Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 136: Latin America 16-Year Perspective for Polycythemia Vera Drugs by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
    • TABLE 137: Latin America Recent Past, Current & Future Analysis for Polycythemia Vera Drugs by Drug Type - Dasatinib, Idelalisib, Givinostat and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Latin America Historic Review for Polycythemia Vera Drugs by Drug Type - Dasatinib, Idelalisib, Givinostat and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 139: Latin America 16-Year Perspective for Polycythemia Vera Drugs by Drug Type - Percentage Breakdown of Value Sales for Dasatinib, Idelalisib, Givinostat and Other Types for the Years 2014, 2025 & 2030
    • TABLE 140: Latin America Recent Past, Current & Future Analysis for Polycythemia Vera Drugs by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Latin America Historic Review for Polycythemia Vera Drugs by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 142: Latin America 16-Year Perspective for Polycythemia Vera Drugs by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • ARGENTINA
    • TABLE 143: Argentina Recent Past, Current & Future Analysis for Polycythemia Vera Drugs by Drug Type - Dasatinib, Idelalisib, Givinostat and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Argentina Historic Review for Polycythemia Vera Drugs by Drug Type - Dasatinib, Idelalisib, Givinostat and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 145: Argentina 16-Year Perspective for Polycythemia Vera Drugs by Drug Type - Percentage Breakdown of Value Sales for Dasatinib, Idelalisib, Givinostat and Other Types for the Years 2014, 2025 & 2030
    • TABLE 146: Argentina Recent Past, Current & Future Analysis for Polycythemia Vera Drugs by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Argentina Historic Review for Polycythemia Vera Drugs by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 148: Argentina 16-Year Perspective for Polycythemia Vera Drugs by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • BRAZIL
    • TABLE 149: Brazil Recent Past, Current & Future Analysis for Polycythemia Vera Drugs by Drug Type - Dasatinib, Idelalisib, Givinostat and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Brazil Historic Review for Polycythemia Vera Drugs by Drug Type - Dasatinib, Idelalisib, Givinostat and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 151: Brazil 16-Year Perspective for Polycythemia Vera Drugs by Drug Type - Percentage Breakdown of Value Sales for Dasatinib, Idelalisib, Givinostat and Other Types for the Years 2014, 2025 & 2030
    • TABLE 152: Brazil Recent Past, Current & Future Analysis for Polycythemia Vera Drugs by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Brazil Historic Review for Polycythemia Vera Drugs by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 154: Brazil 16-Year Perspective for Polycythemia Vera Drugs by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • MEXICO
    • TABLE 155: Mexico Recent Past, Current & Future Analysis for Polycythemia Vera Drugs by Drug Type - Dasatinib, Idelalisib, Givinostat and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Mexico Historic Review for Polycythemia Vera Drugs by Drug Type - Dasatinib, Idelalisib, Givinostat and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 157: Mexico 16-Year Perspective for Polycythemia Vera Drugs by Drug Type - Percentage Breakdown of Value Sales for Dasatinib, Idelalisib, Givinostat and Other Types for the Years 2014, 2025 & 2030
    • TABLE 158: Mexico Recent Past, Current & Future Analysis for Polycythemia Vera Drugs by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Mexico Historic Review for Polycythemia Vera Drugs by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 160: Mexico 16-Year Perspective for Polycythemia Vera Drugs by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 161: Rest of Latin America Recent Past, Current & Future Analysis for Polycythemia Vera Drugs by Drug Type - Dasatinib, Idelalisib, Givinostat and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Rest of Latin America Historic Review for Polycythemia Vera Drugs by Drug Type - Dasatinib, Idelalisib, Givinostat and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 163: Rest of Latin America 16-Year Perspective for Polycythemia Vera Drugs by Drug Type - Percentage Breakdown of Value Sales for Dasatinib, Idelalisib, Givinostat and Other Types for the Years 2014, 2025 & 2030
    • TABLE 164: Rest of Latin America Recent Past, Current & Future Analysis for Polycythemia Vera Drugs by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Rest of Latin America Historic Review for Polycythemia Vera Drugs by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 166: Rest of Latin America 16-Year Perspective for Polycythemia Vera Drugs by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • MIDDLE EAST
    • Polycythemia Vera Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 167: Middle East Recent Past, Current & Future Analysis for Polycythemia Vera Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 168: Middle East Historic Review for Polycythemia Vera Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 169: Middle East 16-Year Perspective for Polycythemia Vera Drugs by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
    • TABLE 170: Middle East Recent Past, Current & Future Analysis for Polycythemia Vera Drugs by Drug Type - Dasatinib, Idelalisib, Givinostat and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Middle East Historic Review for Polycythemia Vera Drugs by Drug Type - Dasatinib, Idelalisib, Givinostat and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 172: Middle East 16-Year Perspective for Polycythemia Vera Drugs by Drug Type - Percentage Breakdown of Value Sales for Dasatinib, Idelalisib, Givinostat and Other Types for the Years 2014, 2025 & 2030
    • TABLE 173: Middle East Recent Past, Current & Future Analysis for Polycythemia Vera Drugs by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Middle East Historic Review for Polycythemia Vera Drugs by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 175: Middle East 16-Year Perspective for Polycythemia Vera Drugs by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • IRAN
    • TABLE 176: Iran Recent Past, Current & Future Analysis for Polycythemia Vera Drugs by Drug Type - Dasatinib, Idelalisib, Givinostat and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Iran Historic Review for Polycythemia Vera Drugs by Drug Type - Dasatinib, Idelalisib, Givinostat and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 178: Iran 16-Year Perspective for Polycythemia Vera Drugs by Drug Type - Percentage Breakdown of Value Sales for Dasatinib, Idelalisib, Givinostat and Other Types for the Years 2014, 2025 & 2030
    • TABLE 179: Iran Recent Past, Current & Future Analysis for Polycythemia Vera Drugs by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Iran Historic Review for Polycythemia Vera Drugs by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 181: Iran 16-Year Perspective for Polycythemia Vera Drugs by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • ISRAEL
    • TABLE 182: Israel Recent Past, Current & Future Analysis for Polycythemia Vera Drugs by Drug Type - Dasatinib, Idelalisib, Givinostat and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Israel Historic Review for Polycythemia Vera Drugs by Drug Type - Dasatinib, Idelalisib, Givinostat and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 184: Israel 16-Year Perspective for Polycythemia Vera Drugs by Drug Type - Percentage Breakdown of Value Sales for Dasatinib, Idelalisib, Givinostat and Other Types for the Years 2014, 2025 & 2030
    • TABLE 185: Israel Recent Past, Current & Future Analysis for Polycythemia Vera Drugs by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Israel Historic Review for Polycythemia Vera Drugs by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 187: Israel 16-Year Perspective for Polycythemia Vera Drugs by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 188: Saudi Arabia Recent Past, Current & Future Analysis for Polycythemia Vera Drugs by Drug Type - Dasatinib, Idelalisib, Givinostat and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Saudi Arabia Historic Review for Polycythemia Vera Drugs by Drug Type - Dasatinib, Idelalisib, Givinostat and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 190: Saudi Arabia 16-Year Perspective for Polycythemia Vera Drugs by Drug Type - Percentage Breakdown of Value Sales for Dasatinib, Idelalisib, Givinostat and Other Types for the Years 2014, 2025 & 2030
    • TABLE 191: Saudi Arabia Recent Past, Current & Future Analysis for Polycythemia Vera Drugs by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Saudi Arabia Historic Review for Polycythemia Vera Drugs by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 193: Saudi Arabia 16-Year Perspective for Polycythemia Vera Drugs by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 194: UAE Recent Past, Current & Future Analysis for Polycythemia Vera Drugs by Drug Type - Dasatinib, Idelalisib, Givinostat and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 195: UAE Historic Review for Polycythemia Vera Drugs by Drug Type - Dasatinib, Idelalisib, Givinostat and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 196: UAE 16-Year Perspective for Polycythemia Vera Drugs by Drug Type - Percentage Breakdown of Value Sales for Dasatinib, Idelalisib, Givinostat and Other Types for the Years 2014, 2025 & 2030
    • TABLE 197: UAE Recent Past, Current & Future Analysis for Polycythemia Vera Drugs by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 198: UAE Historic Review for Polycythemia Vera Drugs by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 199: UAE 16-Year Perspective for Polycythemia Vera Drugs by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 200: Rest of Middle East Recent Past, Current & Future Analysis for Polycythemia Vera Drugs by Drug Type - Dasatinib, Idelalisib, Givinostat and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Rest of Middle East Historic Review for Polycythemia Vera Drugs by Drug Type - Dasatinib, Idelalisib, Givinostat and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 202: Rest of Middle East 16-Year Perspective for Polycythemia Vera Drugs by Drug Type - Percentage Breakdown of Value Sales for Dasatinib, Idelalisib, Givinostat and Other Types for the Years 2014, 2025 & 2030
    • TABLE 203: Rest of Middle East Recent Past, Current & Future Analysis for Polycythemia Vera Drugs by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Rest of Middle East Historic Review for Polycythemia Vera Drugs by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 205: Rest of Middle East 16-Year Perspective for Polycythemia Vera Drugs by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • AFRICA
    • Polycythemia Vera Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 206: Africa Recent Past, Current & Future Analysis for Polycythemia Vera Drugs by Drug Type - Dasatinib, Idelalisib, Givinostat and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Africa Historic Review for Polycythemia Vera Drugs by Drug Type - Dasatinib, Idelalisib, Givinostat and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 208: Africa 16-Year Perspective for Polycythemia Vera Drugs by Drug Type - Percentage Breakdown of Value Sales for Dasatinib, Idelalisib, Givinostat and Other Types for the Years 2014, 2025 & 2030
    • TABLE 209: Africa Recent Past, Current & Future Analysis for Polycythemia Vera Drugs by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Africa Historic Review for Polycythemia Vera Drugs by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 211: Africa 16-Year Perspective for Polycythemia Vera Drugs by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030

IV. COMPETITION